Cannabis and Dementia: Can Cannabinoids Help Alzheimer’s Patients?

The Endocannabinoid System and Neurodegeneration

• CB1 and CB2 receptors are distributed throughout brain regions affected by Alzheimer’s disease including the hippocampus and prefrontal cortex
• Preclinical research suggests cannabinoids reduce amyloid-beta plaque formation and tau protein phosphorylation, two hallmarks of Alzheimer’s pathology
• Neuroinflammation, a key driver of neurodegeneration, is modulated by endocannabinoid signalling via CB2 receptor activation on microglia
• THC and CBD both demonstrate antioxidant properties that may protect neurons from the oxidative stress associated with dementia

The endocannabinoid system plays a significant role in the pathological processes underlying Alzheimer’s disease, providing a biological rationale for cannabinoid-based interventions.

Clinical Evidence: Managing Behavioural Symptoms

• Agitation and aggression, common and distressing in dementia, have been studied in several small controlled trials of cannabis
• A 2019 Israeli study found that medical cannabis significantly reduced agitation scores in dementia patients over eight weeks
• CBD appears particularly promising for managing anxiety and sleep disturbance without the psychoactive effects associated with THC
• Appetite stimulation is a well-established effect of THC that may benefit dementia patients with cachexia or poor oral intake

While cannabis cannot reverse the underlying disease process, the evidence for symptom management in dementia — particularly behavioural and psychological symptoms — is increasingly encouraging.

UK Prescribing for Dementia Patients

• Dementia patients are a vulnerable population requiring careful risk-benefit assessment before cannabis prescribing
• Cognitive side effects of THC are a significant concern; CBD-dominant or balanced products are generally preferred
• A geriatrician or old-age psychiatrist should ideally be involved in initiating or supervising cannabis treatment in this group
• Carer involvement is essential given the cognitive impairment that prevents full informed consent in advanced dementia

Specialist prescribers in the UK are increasingly willing to consider cannabis for behavioural symptoms of dementia when standard pharmacological options have been exhausted or are poorly tolerated.

What Families Should Know

• The primary goal in dementia is quality of life and reduction of distress, not disease modification
• Low-dose CBD oils available as food supplements should not be conflated with prescription-grade medical cannabis
• Families should seek a referral to a specialist prescribing clinic with experience in elderly or cognitively impaired patients
• Regular review of the ongoing clinical benefit is essential, as the risk-benefit balance can shift as the disease progresses

For families navigating the complex decisions around dementia care, medical cannabis represents a legitimate option worth discussing with a specialist, particularly when conventional approaches prove inadequate.